TransCelerate Advances Digital Protocols in Clinical Trials

TransCelerate is advancing its Digital Data Flow (DDF) initiative to modernize clinical trials by embracing digital protocols, announced in a press release. The initiative aims to address the industry's reliance on unstructured documents, which currently account for 90% of clinical trial protocols, by promoting the adoption of structured, digital formats.

At recent events in the U.S. and Europe, TransCelerate highlighted the growing industry momentum towards digital protocols, with participation from sponsors, regulators, and solution providers. These events showcased the benefits of the Unified Study Definitions Model (USDM) version 4, which provides a standardized, machine-readable format for clinical trial protocols, facilitating automation and data reuse.

The adoption of digital protocols is expected to enhance regulatory compliance, improve efficiency, and foster innovation across the clinical trial ecosystem. TransCelerate's efforts align with global regulatory trends and are supported by its member companies, who collectively invest $125 billion annually in research and development.